Angex Pharmaceutical Inc Information

Angex is a biopharmaceutical company focusing on the discovery and development of proprietary small-molecule targeted therapies in oncology. Angex founders are industry veterans with decades of seasoned R&D experience in US-based major pharmaceutical companies. Their R&D track records include two marketed drugs for oncology. Angex has a focused approach on gnomically defined cancers as well as targeting biomarker-driven patient populations with clinically relevant mutations and acquired resistance. Angex is developing a wide-range of drug candidates at the frontiers of immuno oncology, kinase inhibitors and epigenetics with the potential to reshape the landscape of cancer therapies and precision medicines. A number of programs are undergoing IND-enabling studies in preparation to file for clinical trials. Email: angexpharma@angexpharmaceutical.com